DR-30310

N/A

Report date: 2026/03/19 17:01:24

Base Information

Drug NameDR-30310

Drug Alias NameDR-30310

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionClaudin-18 splice variant 2 antagonistsT cell surface glycoprotein CD3 stimulantsAnti-Serum albumin

TargetsClaudin-18 splice variant 2Serum albuminT-cell surface glycoprotein CD3 epsilon chain +[4]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesZhejiang Doer Biologics Corp

China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Doer Biologics Corp

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A